Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 09, 2023

BUY
$0.24 - $0.76 $3 - $11
15 Added 3.05%
506 $0
Q3 2022

Nov 10, 2022

SELL
$0.85 - $1.65 $1,389 - $2,697
-1,635 Reduced 76.9%
491 $0
Q2 2022

Aug 10, 2022

BUY
$1.04 - $1.86 $719 - $1,287
692 Added 48.26%
2,126 $3,000
Q1 2022

May 12, 2022

SELL
$1.44 - $5.62 $6,373 - $24,874
-4,426 Reduced 75.53%
1,434 $3,000
Q4 2021

Feb 10, 2022

BUY
$5.03 - $11.63 $17,760 - $41,065
3,531 Added 151.61%
5,860 $31,000
Q3 2021

Nov 10, 2021

BUY
$9.29 - $14.27 $21,636 - $33,234
2,329 New
2,329 $22,000

About Oncorus, Inc.


  • Ticker ONCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,973,100
  • Description
  • Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...
More about ONCR
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.